NO2020009I1 - Metformin eller et farmasøytisk akseptabelt salt derav; saksagliptin eller et farmasøytisk akseptabelt salt derav; dapagliflozin eller et farmasøytisk akseptabelt solvat derav - Google Patents

Metformin eller et farmasøytisk akseptabelt salt derav; saksagliptin eller et farmasøytisk akseptabelt salt derav; dapagliflozin eller et farmasøytisk akseptabelt solvat derav

Info

Publication number
NO2020009I1
NO2020009I1 NO2020009C NO2020009C NO2020009I1 NO 2020009 I1 NO2020009 I1 NO 2020009I1 NO 2020009 C NO2020009 C NO 2020009C NO 2020009 C NO2020009 C NO 2020009C NO 2020009 I1 NO2020009 I1 NO 2020009I1
Authority
NO
Norway
Prior art keywords
pharmaceutically acceptable
acceptable salt
dapagliflozin
saxagliptin
metformin
Prior art date
Application number
NO2020009C
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Astrazeneca Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43413352&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2020009(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab, Astrazeneca Uk Ltd filed Critical Astrazeneca Ab
Publication of NO2020009I1 publication Critical patent/NO2020009I1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO2020009C 2009-11-13 2020-05-04 Metformin eller et farmasøytisk akseptabelt salt derav; saksagliptin eller et farmasøytisk akseptabelt salt derav; dapagliflozin eller et farmasøytisk akseptabelt solvat derav NO2020009I1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26108709P 2009-11-13 2009-11-13
PCT/US2010/056529 WO2011060256A2 (en) 2009-11-13 2010-11-12 Bilayer tablet formulations

Publications (1)

Publication Number Publication Date
NO2020009I1 true NO2020009I1 (no) 2020-05-04

Family

ID=43413352

Family Applications (1)

Application Number Title Priority Date Filing Date
NO2020009C NO2020009I1 (no) 2009-11-13 2020-05-04 Metformin eller et farmasøytisk akseptabelt salt derav; saksagliptin eller et farmasøytisk akseptabelt salt derav; dapagliflozin eller et farmasøytisk akseptabelt solvat derav

Country Status (20)

Country Link
US (4) US8535715B2 (no)
EP (2) EP3315124B1 (no)
JP (4) JP5775522B2 (no)
CN (2) CN102711739B (no)
BR (1) BR112012011726A2 (no)
CA (2) CA2987757C (no)
CY (2) CY1122575T1 (no)
DK (1) DK2498758T3 (no)
ES (2) ES2689107T3 (no)
HR (1) HRP20181347T1 (no)
HU (2) HUE040486T2 (no)
LT (2) LT2498758T (no)
MX (1) MX345777B (no)
NO (1) NO2020009I1 (no)
PL (1) PL2498758T3 (no)
PT (1) PT2498758T (no)
RS (1) RS57756B1 (no)
RU (2) RU2712757C3 (no)
SI (1) SI2498758T1 (no)
WO (1) WO2011060256A2 (no)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2395983T3 (pl) 2009-02-13 2020-09-07 Boehringer Ingelheim International Gmbh Kompozycja farmaceutyczna zawierająca inhibitor sglt2, inhibitor dpp-iv i ewentualnie dalszy środek przeciwcukrzycowy oraz jej zastosowania
DK2498759T3 (en) * 2009-11-13 2018-11-26 Astrazeneca Ab TABLE FORMULATIONS WITH IMMEDIATE RELEASE
JP5775522B2 (ja) 2009-11-13 2015-09-09 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ 二層錠製剤
TWI631963B (zh) * 2011-01-05 2018-08-11 雷西肯製藥股份有限公司 包含鈉－葡萄糖共同輸送體１與２之抑制劑的組合物與應用方法
UY33937A (es) * 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
US20140248345A1 (en) * 2011-10-24 2014-09-04 Merck Sharp & Dohme Corp. Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with atorvastatin
US20130189358A1 (en) * 2012-01-10 2013-07-25 Roey Solomonovich Saxagliptin pharmaceutical formulations
US10973768B2 (en) * 2012-03-01 2021-04-13 Bristol-Myers Squibb Company Extended release pharmaceutical formulations of water-soluble active pharmaceutical ingredients and methods for making the same
US9555001B2 (en) * 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
TR201202948A2 (tr) 2012-03-15 2012-07-23 Ali̇ Rai̇f İlaç Sanayi̇ A.Ş. Dapagliflozin ve uzatılmış salınımlı metaformin içeren tablet formülasyonu.
US10265281B2 (en) 2012-11-02 2019-04-23 Murray And Poole Enterprises Ltd Treatment or prevention of cardiovascular events via the administration of a colchicine derivative
US9675587B2 (en) 2013-03-14 2017-06-13 Allergan Holdings Unlimited Company Opioid receptor modulator dosage formulations
US20140294950A1 (en) * 2013-03-15 2014-10-02 Vivus, Inc. Methods of treating obesity in responder and non-responder populations
EP2783680A1 (en) * 2013-03-25 2014-10-01 Sanovel Ilac Sanayi ve Ticaret A.S. Controlled-release formulations comprising metformin and gliclazide
MX2015014656A (es) 2013-04-16 2016-03-01 Murray And Poole Entpr Ltd Formulaciones de liberacion prolongada de colchicina y metodos de uso de las mismas.
CN105358553A (zh) * 2013-05-08 2016-02-24 斯洛文尼亚莱柯制药股份有限公司 新的结晶的1-(β-D-吡喃葡萄糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯的水合物
WO2015071887A1 (en) * 2013-11-18 2015-05-21 Ranbaxy Laboratories Limited Oral pharmaceutical compositions of saxagliptin
CN103976997B (zh) * 2014-05-13 2016-08-17 中国药科大学 一种降血糖复方缓释胶囊及其制备方法
CN103933031B (zh) * 2014-05-13 2017-01-18 中国药科大学 一种含有dpp‑4抑制剂和盐酸二甲双胍的复方制剂及其制备方法
EA023747B1 (ru) * 2014-11-13 2016-07-29 Промомед Холдингс Лимитед Фармацевтическая композиция для профилактики и лечения нарушений, связанных с избыточным весом или ожирением (варианты), наборы (варианты), их применение и способ профилактики и лечения нарушений, связанных с избыточным весом или ожирением
WO2016092560A2 (en) * 2014-12-09 2016-06-16 Eris Lifesciences Pvt Ltd. Dual release bilayer tablets comprising metformin
KR102637828B1 (ko) * 2015-06-26 2024-02-20 애브비 인코포레이티드 Hcv의 치료를 위한 고형 약제학적 조성물
JP7133466B2 (ja) * 2015-07-17 2022-09-08 アッヴィ・インコーポレイテッド Ｈｃｖを処置するための固体医薬組成物
CN106924208A (zh) * 2015-12-30 2017-07-07 深圳翰宇药业股份有限公司 一种复方达格列净二甲双胍缓释片及其制备方法
US20190110994A1 (en) * 2016-03-31 2019-04-18 Lupin Limited Pharmaceutical composition of dapagliflozin
CN106176718A (zh) * 2016-08-03 2016-12-07 上海延安药业有限公司 复方卡格列净二甲双胍片
WO2018124497A1 (ko) * 2016-12-30 2018-07-05 한미약품 주식회사 다파글리플로진 l-프롤린과 항당뇨병제를 포함하는 약제학적 복합 제제
WO2018167589A1 (en) 2017-03-16 2018-09-20 Inventia Healthcare Private Limited Pharmaceutical composition comprising dapagliflozin
CN110753540A (zh) * 2017-06-08 2020-02-04 格兰马克药品有限公司 瑞格列净的口服药物制剂
KR102369679B1 (ko) * 2017-09-29 2022-03-04 한미약품 주식회사 다파글리플로진 l-프롤린과 메트포르민을 포함하는 약제학적 복합제제
MX2020002312A (es) * 2017-09-29 2020-09-17 Hanmi Pharm Ind Co Ltd Farmaceutica combinada que comprende dapagliflozina l-prolina y metformina.
KR101992400B1 (ko) * 2018-04-30 2019-06-24 보령제약 주식회사 약학적 제제
KR102070104B1 (ko) * 2018-06-05 2020-01-29 주식회사 종근당 메트포르민 및 로베글리타존을 포함하는 서방성 약제학적 제제
KR20200005320A (ko) * 2018-07-06 2020-01-15 한미약품 주식회사 무정형의 다파글리플로진 l-프롤린을 포함하는 약학적 제제 및 이의 제조방법
CN109432030A (zh) * 2018-12-03 2019-03-08 瀚晖制药有限公司 一种沙格列汀二甲双胍双层片及其制备方法
MX2021009755A (es) * 2019-02-13 2021-11-17 Iterum Therapeutics International Ltd Combinaciones de compuestos beta-lactámicos y probenecid, y usos de los mismos.
TR201914043A1 (tr) * 2019-09-16 2021-04-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dapagli̇flozi̇n ve metformi̇n i̇çeren efervesan tablet formülasyonlari
TR201916829A2 (tr) * 2019-10-31 2021-05-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dapagli̇flozi̇n ve metformi̇n i̇çeren çi̇ft katmanli tablet formülasyonlari
EP4106732A1 (en) * 2020-02-21 2022-12-28 Zaklady Farmaceutyczne Polpharma S.A. Pharmaceutical composition comprising dapagliflozin
WO2021176096A1 (en) 2020-03-05 2021-09-10 Krka, D.D., Novo Mesto Pharmaceutical composition comprising sglt2 inhibitor
KR20210121599A (ko) * 2020-03-30 2021-10-08 한미약품 주식회사 시타글립틴, 다파글리플로진, 및 메트포르민을 포함하는 경구용 복합정제
EP4161912A1 (en) 2020-06-05 2023-04-12 KRKA, d.d., Novo mesto Preparation of highly pure amorphous dapagliflozin
WO2022115053A1 (en) * 2020-11-27 2022-06-02 Santa Farma Ilac Sanayii A.S. Multi-layered tablet formulation with extended release layer of metformin hydrochloride
TR202019590A2 (tr) 2020-12-03 2022-06-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dapagli̇flozi̇n ve metformi̇n hi̇droklorür formülasyonlarina yöneli̇k bi̇r proses
WO2022119543A1 (en) 2020-12-03 2022-06-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A process for tablet formulations comprising amorphous dapagliflozin and metformin hydrochloride
CN112546013B (zh) * 2020-12-29 2022-06-10 平光制药股份有限公司 一种沙格列汀二甲双胍双层片及其制备工艺
CN112933057A (zh) * 2021-02-03 2021-06-11 浙江诺得药业有限公司 一种卡格列净复方控释片及其制备方法
EP4079296A1 (en) * 2021-04-21 2022-10-26 Sanovel Ilac Sanayi Ve Ticaret A.S. A bilayer tablet formulation comprising amorphous dapagliflozin and metformin
KR20230009020A (ko) * 2021-07-08 2023-01-17 한미약품 주식회사 시타글립틴, 다파글리플로진 및 메트포르민을 포함하는 경구용 복합정제
WO2023136797A2 (en) * 2022-01-13 2023-07-20 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A bilayer tablet composition comprising amorphous dapagliflozin and metformin
EP4212150A1 (en) * 2022-01-13 2023-07-19 Sanovel Ilac Sanayi Ve Ticaret A.S. A bilayer tablet composition comprising amorphous dapagliflozin and metformin
CN115414347B (zh) * 2022-08-22 2023-09-15 北京诺和德美医药技术有限公司 一种缓释片及其制备方法与应用

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US100000A (en) 1870-02-22 Improved sun-bonnet for horses
US3674836A (en) 1968-05-21 1972-07-04 Parke Davis & Co 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof
US4027009A (en) 1973-06-11 1977-05-31 Merck & Co., Inc. Compositions and methods for depressing blood serum cholesterol
JPS5612114B2 (no) 1974-06-07 1981-03-18
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
DK149080C (da) 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US4450171A (en) 1980-08-05 1984-05-22 Merck & Co., Inc. Antihypercholesterolemic compounds
US4448784A (en) 1982-04-12 1984-05-15 Hoechst-Roussel Pharmaceuticals, Inc. 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4499289A (en) 1982-12-03 1985-02-12 G. D. Searle & Co. Octahydronapthalenes
CA1327360C (en) 1983-11-14 1994-03-01 William F. Hoffman Oxo-analogs of mevinolin-like antihypercholesterolemic agents
US4613610A (en) 1984-06-22 1986-09-23 Sandoz Pharmaceuticals Corp. Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives
US4686237A (en) 1984-07-24 1987-08-11 Sandoz Pharmaceuticals Corp. Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof
US4647576A (en) 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
WO1986003488A1 (en) 1984-12-04 1986-06-19 Sandoz Ag Indene analogs of mevalonolactone and derivatives thereof
US4668794A (en) 1985-05-22 1987-05-26 Sandoz Pharm. Corp. Intermediate imidazole acrolein analogs
AU598775B2 (en) 1985-10-25 1990-07-05 Sandoz Ag Heterocyclic analogs of mevalonolactone
FR2596393B1 (fr) 1986-04-01 1988-06-03 Sanofi Sa Derives de l'acide hydroxy-3 dihydroxyoxophosphorio-4 butanoique, leur procede de preparation, leur application comme medicament et les compositions les renfermant
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
GR1000959B (el) 1987-05-22 1993-03-16 Squibb & Sons Inc ΑΝΑΣΤΟΛΕΙΣ ΤΗΣ ΡΕΔΟΥΚΤΑΣΗΣ HMG-CοA ΠΟΥ ΠΕΡΙΕΧΕΙ ΦΩΣΦΟΡΟ,ΝΕΑ ΕΝΔΙΑΜΕΣΑ ΚΑΙ ΜΕΘΟΔΟΣ
US4759923A (en) 1987-06-25 1988-07-26 Hercules Incorporated Process for lowering serum cholesterol using poly(diallylmethylamine) derivatives
JP2569746B2 (ja) 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
US4871721A (en) 1988-01-11 1989-10-03 E. R. Squibb & Sons, Inc. Phosphorus-containing squalene synthetase inhibitors
US4924024A (en) 1988-01-11 1990-05-08 E. R. Squibb & Sons, Inc. Phosphorus-containing squalene synthetase inhibitors, new intermediates and method
NO177005C (no) 1988-01-20 1995-07-05 Bayer Ag Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen
US5506219A (en) 1988-08-29 1996-04-09 E. R. Squibb & Sons, Inc. Pyridine anchors for HMG-CoA reductase inhibitors
US5753675A (en) 1989-03-03 1998-05-19 Novartis Pharmaceuticals Corporation Quinoline analogs of mevalonolactone and derivatives thereof
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5177080A (en) 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
US5595872A (en) 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
US5470845A (en) 1992-10-28 1995-11-28 Bristol-Myers Squibb Company Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia
US5594016A (en) 1992-12-28 1997-01-14 Mitsubishi Chemical Corporation Naphthalene derivatives
CA2150372C (en) 1993-01-19 2002-08-20 Nancy L. Mills Stable oral ci-981 formulation and process of preparing same
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US5776983A (en) 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
US5488064A (en) 1994-05-02 1996-01-30 Bristol-Myers Squibb Company Benzo 1,3 dioxole derivatives
US5385929A (en) 1994-05-04 1995-01-31 Warner-Lambert Company [(Hydroxyphenylamino) carbonyl] pyrroles
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
DE4432757A1 (de) * 1994-09-14 1996-03-21 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
US5491134A (en) 1994-09-16 1996-02-13 Bristol-Myers Squibb Company Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives
US5541204A (en) 1994-12-02 1996-07-30 Bristol-Myers Squibb Company Aryloxypropanolamine β 3 adrenergic agonists
US5620997A (en) 1995-05-31 1997-04-15 Warner-Lambert Company Isothiazolones
WO1997012613A1 (en) 1995-10-05 1997-04-10 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
CA2240024A1 (en) 1995-12-13 1997-06-19 The Regents Of The University Of California Nuclear receptor ligands and ligand binding domains
US5770615A (en) 1996-04-04 1998-06-23 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
US5962440A (en) 1996-05-09 1999-10-05 Bristol-Myers Squibb Company Cyclic phosphonate ester inhibitors of microsomal triglyceride transfer protein and method
US5827875A (en) 1996-05-10 1998-10-27 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US5885983A (en) 1996-05-10 1999-03-23 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US5760246A (en) 1996-12-17 1998-06-02 Biller; Scott A. Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
GB9713739D0 (en) 1997-06-27 1997-09-03 Karobio Ab Thyroid receptor ligands
ES2288807T1 (es) 1998-02-02 2008-02-01 Trustees Of Tufts College Uso de inhibidores de dipeptidasa para regular el metabolismo de la glucosa.
EP1062222A1 (en) 1998-03-09 2000-12-27 Fondatech Benelux N.V. Serine peptidase modulators
EA003101B1 (ru) * 1998-03-19 2002-12-26 Бристол-Майерз Сквибб Компани Двухфазная система доставки с регулируемым высвобождением для фармацевтических средств с высокой растворимостью и способ лечения диабета с помощью этой системы
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
CA2336714A1 (en) 1998-07-06 2000-01-13 Bristol-Myers Squibb Company Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
US6117451A (en) 1998-08-25 2000-09-12 Pharmalogix, Inc. Direct compression metformin hydrochloride tablets
GB9828442D0 (en) 1998-12-24 1999-02-17 Karobio Ab Novel thyroid receptor ligands and method II
US6548529B1 (en) 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
TWI302149B (en) 1999-09-22 2008-10-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
US6515117B2 (en) * 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
MY125516A (en) * 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
US20020177626A1 (en) * 2001-01-19 2002-11-28 Cook Graham D. Treatment of sleep disturbances
HUP0700151A2 (en) 2001-10-18 2007-05-29 Bristol Myers Squibb Co Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
JP2003144528A (ja) * 2001-11-15 2003-05-20 Fancl Corp 多層錠及びその製造方法
RU2004129573A (ru) 2002-04-04 2005-04-10 Пфайзер Продактс Инк. (Us) Жевательная таблетка с приятным вкусом
WO2003105809A1 (en) 2002-06-17 2003-12-24 Themis Laboratories Private Limited Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them
WO2004012715A1 (en) 2002-08-02 2004-02-12 Penwest Pharmaceuticals Company Sustained release formulations of metformin
DE10258007B4 (de) 2002-12-12 2006-02-09 Sanofi-Aventis Deutschland Gmbh Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
WO2004110422A1 (en) * 2003-06-16 2004-12-23 Ranbaxy Laboratories Limited Extended-release tablets of metformin
TWI354569B (en) 2004-05-28 2011-12-21 Bristol Myers Squibb Co Coated tablet formulation and method
DE102004028241B4 (de) 2004-06-11 2007-09-13 Sanofi-Aventis Deutschland Gmbh Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel
AR051446A1 (es) 2004-09-23 2007-01-17 Bristol Myers Squibb Co Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
AU2005299808B2 (en) * 2004-10-25 2009-08-20 Novartis Ag Combination of DPP-IV inhibitor, PPAR antidiabetic and metformin
TWI375560B (en) * 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TW200726755A (en) 2005-07-07 2007-07-16 Astellas Pharma Inc A crystalline choline salt of an azulene derivative
CA2633167A1 (en) 2005-12-16 2007-07-12 Merck & Co., Inc. Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin
TWI370818B (en) 2006-04-05 2012-08-21 Astellas Pharma Inc Cocrystal of c-glycoside derivative and l-proline
ES2300188B1 (es) * 2006-05-24 2009-05-01 Ferrer Internacional, S.A. Comprimido bicapa para la prevencion de los accidentes cardiovasculares.
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
CA2681092A1 (en) 2007-03-15 2008-09-18 Nectid, Inc. Anti-diabetic combinations comprising a slow release biguanide composition and an immediate release dipeptidyl peptidase iv inhibitor composition
PE20090185A1 (es) * 2007-03-22 2009-02-28 Bristol Myers Squibb Co Formulaciones farmaceuticas que contienen un inhibidor sglt2
EP2011808A1 (de) 2007-07-03 2009-01-07 Bayer MaterialScience AG Medizinische Klebstoffe für die Chirurgie
JO3272B1 (ar) 2007-07-19 2018-09-16 Takeda Pharmaceuticals Co مستحضر صلب يشمل ألوجليبتين وميتفورمين هيدروكلوريد
UA107175C2 (uk) 2007-07-26 2014-12-10 Спосіб і сполука, призначені для одержання інгібіторів контранспортера натрій-глюкози 2 типу, варіанти
EP2249643A4 (en) 2008-02-05 2013-10-09 Merck Sharp & Dohme PHARMACEUTICAL COMPOSITIONS OF A METFORMIN AND DIPEPTIDYL PEPTIDASE-IV INHIBITOR ASSOCIATION
EP2259676A4 (en) 2008-03-04 2011-03-16 Merck Sharp & Dohme PHARMACEUTICAL COMPOSITIONS OF A COMBINATION OF METFORMIN AND A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
KR101512386B1 (ko) * 2008-04-08 2015-04-17 제이더블유중외제약 주식회사 미티글리나이드 및 메트포르민 복합제제 및 그의 제조방법
US8603989B2 (en) 2008-05-22 2013-12-10 Bristol-Myers Squibb Company Method for treating and preventing kidney stones employing an SGLT2 inhibitor and composition containing same
WO2010045656A2 (en) 2008-10-17 2010-04-22 Nectid, Inc. Novel sglt2 inhibitor dosage forms
PL2395983T3 (pl) 2009-02-13 2020-09-07 Boehringer Ingelheim International Gmbh Kompozycja farmaceutyczna zawierająca inhibitor sglt2, inhibitor dpp-iv i ewentualnie dalszy środek przeciwcukrzycowy oraz jej zastosowania
CA2752437C (en) 2009-02-13 2017-07-11 Boehringer Ingelheim International Gmbh Antidiabetic medications
CN106075451A (zh) 2009-05-27 2016-11-09 阿斯利康(瑞典)有限公司 使用sglt2抑制剂及其组合物在对先前用其它抗糖尿病药进行的治疗具有耐受的患者中治疗ii型糖尿病的方法
UY32919A (es) * 2009-10-02 2011-04-29 Boehringer Ingelheim Int Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
JP5775522B2 (ja) * 2009-11-13 2015-09-09 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ 二層錠製剤
RU2564901C2 (ru) * 2009-11-13 2015-10-10 Бристол-Майерс Сквибб Кампани Композиции метформина с уменьшенной массой
DK2498759T3 (en) * 2009-11-13 2018-11-26 Astrazeneca Ab TABLE FORMULATIONS WITH IMMEDIATE RELEASE

Also Published As

Publication number Publication date
RU2012123947A (ru) 2013-12-20
US9050258B2 (en) 2015-06-09
CA2780939C (en) 2018-06-12
CN105193761A (zh) 2015-12-30
WO2011060256A3 (en) 2012-03-15
LTPA2020003I1 (lt) 2020-05-11
EP3315124B1 (en) 2021-01-06
LT2498758T (lt) 2018-11-26
BR112012011726A2 (pt) 2020-05-19
CN102711739A (zh) 2012-10-03
RS57756B1 (sr) 2018-12-31
MX345777B (es) 2017-02-14
CN105193761B (zh) 2019-12-06
US20130330406A1 (en) 2013-12-12
US9616028B2 (en) 2017-04-11
RU2712757C3 (ru) 2021-06-09
EP3315124A1 (en) 2018-05-02
CY2020008I2 (el) 2020-11-25
SI2498758T1 (sl) 2018-10-30
RU2583920C2 (ru) 2016-05-10
JP5775522B2 (ja) 2015-09-09
AU2010319343B2 (en) 2014-09-18
JP2017081943A (ja) 2017-05-18
JP2015110630A (ja) 2015-06-18
HUE040486T2 (hu) 2019-03-28
DK2498758T3 (en) 2018-10-15
ES2856888T3 (es) 2021-09-28
JP2018172418A (ja) 2018-11-08
CY1122575T1 (el) 2020-07-31
CY2020008I1 (el) 2020-11-25
PT2498758T (pt) 2018-10-23
LTC2498758I2 (lt) 2021-07-12
US20150238421A1 (en) 2015-08-27
JP2013510873A (ja) 2013-03-28
PL2498758T3 (pl) 2019-02-28
RU2016112599A3 (no) 2019-08-20
EP2498758B1 (en) 2018-07-25
CA2987757C (en) 2021-04-13
AU2010319343A1 (en) 2012-07-05
CA2987757A1 (en) 2011-05-19
HRP20181347T1 (hr) 2018-10-19
US8535715B2 (en) 2013-09-17
EP2498758A2 (en) 2012-09-19
WO2011060256A2 (en) 2011-05-19
HUS2000009I1 (hu) 2020-06-29
MX2012005416A (es) 2012-06-14
JP6622862B2 (ja) 2019-12-18
US20170333353A1 (en) 2017-11-23
JP6367299B2 (ja) 2018-08-01
US20120282336A1 (en) 2012-11-08
ES2689107T3 (es) 2018-11-08
RU2016112599A (ru) 2018-11-28
RU2712757C2 (ru) 2020-01-31
CN102711739B (zh) 2015-12-16
CA2780939A1 (en) 2011-05-19

Similar Documents

Publication Publication Date Title
NO2020009I1 (no) Metformin eller et farmasøytisk akseptabelt salt derav; saksagliptin eller et farmasøytisk akseptabelt salt derav; dapagliflozin eller et farmasøytisk akseptabelt solvat derav
NO2020037I1 (no) alpelisib eller et farmasøytisk akseptabelt salt derav
NO2019024I1 (no) Brigatinib eller et farmasøytisk akseptabelt salt derav
NO2020006I1 (no) upadacitinib or a pharmaceutically acceptable salt thereof
NO2022033I1 (no) Rimegepant or a pharmaceutically acceptable salt thereof
NO2020039I1 (no) Ozanimod eller et farmasøytisk akseptabelt salt derav, særlig ozanimodhydroklorid
NO2017059I2 (no) ribosiklib eller et farmasøytisk akseptabelt salt derav
NO2021033I1 (no) Selineksor eller et farmasøytisk akseptabelt salt derav
NO2017057I1 (no) pibrentasvir eller et farmasøytisk akseptabelt salt derav
NO2019027I1 (no) kobicistat eller et farmasøytisk akseptabelt salt derav
NO2020047I1 (no) Remdesivir eller et farmasøytisk akseptabelt salt eller ester derav
NO2020018I1 (no) Darolutamide, optionally in the form of a pharmaceutically acceptable salt or ester thereof
NL301166I2 (nl) Avacopan of een farmaceutisch aanvaardbaar zout daarvan
NO2015012I2 (no) Ombitasvir, eller et farmasøytisk akseptabelt salt derav
NO2023040I1 (no) Atogepant or a pharmaceutically acceptable salt thereof
NO2021018I1 (no) kabotegravir eller et farmasøytisk akseptabelt salt eller solvat derav
FIC20230039I1 (fi) Sedatsuridiini tai tämän farmaseuttisesti hyväksyttävä suola
FIC20200039I1 (fi) Kefiderokoli valinnaisesti farmaseuttisesti hyväksyttävän suolan tai solvaatin muodossa
NO2022044I1 (no) daridorexant eller et farmasøytisk akseptabelt salt derav, spesielt daridorexant hydroklorid
NO2017021I1 (no) Etelkalsetid, eller et salt derav, inkludert etelkalsetidhydroklorid
NO2019019I1 (no) Doravirin eller et farmasøytisk akseptabelt salt derav
NO2020001I1 (no) Gilteritinib eller et salt derav
NO2017024I1 (no) Elosulfase alfa eller et farmasøytisk akseptabelt salt derav
NO2017006I1 (no) Elbasvir eller et farmasøytisk akseptabelt stoff derav
NO2018016I2 (no) Niraparib eller et farmasøytisk akseptabelt salt, stereoisomer eller tautomer derav